Skip to content
Clinical Trials – home
NorwayBack to Norway

Clinical trials in Ski – page 15

623 clinical trials in Ski, Norway across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Ski at a glance
623
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

623 trials in Ski

Open in trial search

Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Oslo University Hospital HF

Study on Emicizumab and Drug Combination for Patients with Haemophilia A and FVIII Inhibitors

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:Emory University

Study on Treatment Strategies for Children and Adolescents with Juvenile Idiopathic Arthritis Using Methotrexate and Drug Combination

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Adalimumab
  • Sponsor:Oslo University Hospital HF

Breast cancer

Recruiting

Study on Personalized Treatment for Hormone Receptor Positive HER2 Negative Breast Cancer Using Capivasertib, Letrozole, and Bevacizumab for Eligible Patients

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Oslo University Hospital HF

Study of zongertinib tablets in patients with advanced solid tumors that have HER2 gene changes

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zongertinib
  • Sponsor:Boehringer Ingelheim Espana S.A.

Breast cancer

Recruiting

Study on Breast Cancer Treatment with Carboplatin for Patients in Neoadjuvant and Metastatic Stages

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Oslo University Hospital HF

Study on Long-Term Use of Infigratinib for Children with Achondroplasia

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Infigratinib
  • Sponsor:Qed Therapeutics Inc.

Uveal melanoma

Recruiting

Title: Comparing tebentafusp treatment versus observation in patients with high-risk eye melanoma (uveal melanoma) after initial treatment

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Tebentafusp
  • Sponsor:European Organisation For Research And Treatment Of Cancer

Cataract

Recruiting

Study on Reducing Inflammation After Cataract Surgery Using Nepafenac and Dexamethasone for Patients Undergoing Surgery

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Oslo University Hospital HF

Study on Bortezomib and Temozolomide for Patients with Recurrent Grade IV Glioma

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Helse Bergen HF

Diabetes mellitus+1

Recruiting

Study on the Safety and Effectiveness of VX-880 for Patients with Type 1 Diabetes and Severe Low Blood Sugar Awareness

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Zimislecel
  • Sponsor:Vertex Pharmaceuticals Inc.

Study of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Other cities in Norway

The busiest research cities in the country

All 53 cities in Norway
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.